4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InspireMD, Inc. (NSPR) operates in the Medical Devices industry and is headquartered in Miami, United States with about 127 employees. Its market capitalization is roughly $33 million. In the fiscal year ended 2025-12-31, NSPR reported $9M in revenue and ($49M) in net income.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally.
Interactive charts & full statements → Open the NSPR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $9M | $7M | $6M | $5M | — |
| Gross Profit | $3M | $2M | $2M | $1M | — |
| Operating Income (EBIT) | ($50M) | ($34M) | ($21M) | ($19M) | — |
| Net Income | ($49M) | ($32M) | ($20M) | ($18M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $3M | $3M | $2M | $2M | $2M | — |
| Gross Profit | $1M | $1M | $1M | $0M | $0M | — |
| Operating Income (EBIT) | ($14M) | ($12M) | ($13M) | ($13M) | ($12M) | — |
| Net Income | ($14M) | ($12M) | ($13M) | ($13M) | ($11M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $69M | $47M | $48M | $25M |
| Total Liabilities | $14M | $11M | $8M | $7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NSPR viewer.
About TickerBase · Data methodology & sources